A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

Running, not enrolling · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)

In brief

The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 * evaluate the efficacy, safety, tolerability, PK, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM

Key facts

Study ID
NCT06845202
Run by
Alnylam Pharmaceuticals
People needed
105
Starts
2025-03-03
Expected to finish
2027-08-31
Last updated by the study team
2026-07-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.